1:45PM – 2:30PM
KEYNOTE From “Most Admired” to “Pharma Bros”: How Biopharmaceutical Companies Have Allowed the Debate on Drug Pricing to Steal Their Reputation – and What Communications Professionals Can Do to Help Get It Back
Ron Cohen, M.D., Founder, Chief Executive Officer and President, ACORDA THERAPEUTICS
Interviewed by: Tierney Saccavino, Executive Vice President, Corporate Communications, ACORDA THERAPEUTICS
In the 1980s and 1990s, Merck was ranked the most admired company in America seven years in a row. Compare that to today’s headlines: “Drug price strategy enriches company, but infuriates patients and lawmakers,” “Cancer patient, outraged by sky-high drug prices, organizes others to fight them,” “Drug goes from $13.50 a tablet to $750, overnight.” The biopharmaceutical industry is in a crisis and must take action to regain its credibility and reputation.
Join Dr. Cohen in a moderated discussion in which he provides his insights on where industry pricing models are heading, the potential for legislative action, and what companies must do to re-establish trust with the public and patient communities they serve.